Denmark stocks were lower after the close on Tuesday, as losses in the Real Estate, Oil & Gas and Healthcare sectors led ...

Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat Novo Nordisk's Ozempic (semaglutide) at lowering glycated hemoglobin (HbA1c) ...

DEMAND for fat jabs could overwhelm the NHS, the head of the health service has warned as Sir Keir Starmer piled hopes on using them to get obese jobseekers back to work. Amanda Pritchard, CEO of ...

Conclusion: The Karnataka High Court, upholding the ITAT’s order, reiterated that discounts on the issuance of ESOPs are allowable deductions under Section 37 (1) of the Income Tax Act, in line with ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

A study will assess changes in employment status and sick days when people take the drug. Weight loss drugs could be given to unemployed people with obesity as a way of getting them into work, British ...

France’s Economy Minister has warned that the government could block the sale of a subsidiary of the French pharmaceutical ...

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Novo Nordisk filed suit against another semaglutide compounder on Friday, bringing its total number of cases to 50. Both Novo ...

An investigational oral fatty acid synthase (FASN) inhibitor was associated with significant improvements in metabolic ...

Drugs like Ozempic and Wegovy may provide a surprising, life-saving benefit for the youngest patients taking these diabetes and weight loss medications.

AZN currently has a forward P/E ratio of 19.02, while NVO has a forward P/E of 39.15. We also note that AZN has a PEG ratio of 1.43. This metric is used similarly to the famous P/E ratio, but the PEG ...